Loading viewer...
other
Format: PDF other
Comprehensive overview of Roche's pharmaceutical development portfolio as of July 2023, including new molecular entities (NMEs) and additional indications (AIs) across oncology, immunology, neuroscience, and other therapeutic areas. The pipeline shows progress with approvals, new entries into development phases, and removals, spanning research through marketed products across Roche Pharma, Genentech, and affiliated entities.
other
31 Pages
Automatic Data Processing
SITE Centers 1Q24 Earnings Conference Call April 2024
otherother
28 Pages
SITE Centers Corp.
Invacare Corporation 2021 UBS Global Healthcare Conference
otherother
13 Pages
Invacare Corporation